Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency

Therapeutic Advances in Respiratory Disease
Gema Tirado-CondeMarc Miravitlles

Abstract

Alpha-1 antitrypsin deficiency (AAT) is a hereditary recessive autosomal disease caused by mutations in the AAT gene. This disease is characterized by abnormally low AAT concentrations in plasma, which, in its homozygote form, carries a high risk for the development of early pulmonary emphysema and liver damage. Since the end of the 1980s augmentation therapy with AAT from human plasma has been available for specific treatment of emphysema due to AAT deficiency. Intravenous augmentation therapy has been demonstrated to be safe and weekly infusions of AAT have resulted in plasma AAT concentrations above those considered protective for the lungs. However, life-long weekly infusions are not well accepted by patients, therefore pharmacokinetic studies have been performed to try to individualize the therapeutic regimen in order to obtain adequate trough serum AAT levels with prolonged intervals of administration. Therapeutic regimens administered every two weeks appear to be safe and result in adequate trough serum concentrations, but less-frequent administrations result in trough levels below the target. Alpha-1-antitrypsin deficiency is largely unrecognized and underdiagnosed. The foundation of national and international registrie...Continue Reading

References

Apr 23, 1987·The New England Journal of Medicine·M D WewersR G Crystal
Dec 1, 1994·Archivos de bronconeumología·M MiravitllesJ de Gracia
Jan 1, 1997·Respiration; International Review of Thoracic Diseases·M SchwaiblmairG Fruhmann
Nov 11, 1999·American Journal of Respiratory and Critical Care Medicine·A DirksenJ Stolk
Mar 13, 2001·Chest·M WenckerUNKNOWN Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen
Jun 5, 2002·American Journal of Respiratory and Critical Care Medicine·Robert A StockleyLee J Dowson
Sep 6, 2002·The European Respiratory Journal·M WenckerE J Campbell
Oct 3, 2003·American Journal of Respiratory and Critical Care Medicine·UNKNOWN American Thoracic Society, UNKNOWN European Respiratory Society
Jun 3, 2005·The European Respiratory Journal·M Needham, R A Stockley
Jun 23, 2005·Medicina clínica·Marc Miravitlles
Jul 27, 2005·Respiratory Medicine·Luciano CordaClaudio Tantucci
Oct 6, 2005·The European Respiratory Journal·C de la RozaM Miravitlles
Oct 21, 2005·Chest·James K StollerCharlie Strange
Jul 11, 2006·Archivos de bronconeumología·Cristian de la RozaMarc Miravitlles
Mar 3, 2007·The European Respiratory Journal·R A StockleyUNKNOWN Alpha One International Registry (AIR) group
Mar 29, 2007·Thorax·Dawn L DemeoEdwin K Silverman

❮ Previous
Next ❯

Citations

Mar 8, 2011·Clinics and Research in Hepatology and Gastroenterology·Ahmed A DarwishChristophe Chardot
Mar 1, 2012·Current Opinion in Pharmacology·Marc Miravitlles
Feb 1, 2012·Therapeutic Advances in Respiratory Disease·Francisco Rodriguez-FriasRosendo Jardi
Feb 23, 2012·Therapeutic Advances in Respiratory Disease·Juan Carlos Barros-TizónUNKNOWN Investigators of the rEXA study group
Mar 27, 2013·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Jacqueline LeßigInes Neundorf
Aug 9, 2020·Journal of Clinical Medicine·José Luis López-CamposCandelaria Caballero Eraso

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.